- (1.) M.A. 2570/2018 in C.A.Nos. 22982-23404/2017, M.A. 2574/2018 in C.A. Nos. 22982-23404/2017 & M.A. No. 2810/2018 in C.A. Nos. 22982- 23404/2017 : Insofar as the above applications are concerned, the Government has issued notifications the effect of which is to remove the ban on the Fixed Dose Combinations that is involved in these applications, manufactured by Cipla Ltd. And Unison Pharmaceuticals Ltd. & Medopharm Pvt. Ltd.
(2.) These Applications are, therefore, disposed of as being infructuous. M.A. No. 600/2018 in C.A. No. 23405-23472/2017, M.A. No. 1729/2018 in T.C. (C) No. 30/2017, M.A. No. 2466/2018 in C.A. Nos. 22982- 23404/2017, M.A. No. 2470/2018 in C.A. Nos. 22982-23404/2017, M.A. No. 2533/2018 in C.A. Nos. 22982-23404/2017, M.A. No. 2535/2018 in C.A. Nos. 22982-23404/2017, M.A. No. 2574/2018 in C.A. Nos. 22982- 23404/2017 & M.A. 2856-286/2018 in C.A. Nos. 22973-22981/2017 :
(3.) Insofar as the above applications are concerned, the drugs in question i.e. Paracetamol + Propyphenazone + Caffeine/Ammonium Chloride + Sodium Citrate + Chlorpheniramine Maleate + Menthol/ Salbutamol+ Hydroxyethyltheophylline (Etofylline) + Bromhexine/ Chlorpheniramine Maleate + Ammonium Chloride + Sodium Citrate claim to be manufactured pre-1988. Hence, they would be at par with the list of 15 drugs that were referred to in our judgment in Union of India & Anr. vs. Pfizer Limited & Ors ., 2018 2 SCC 39.;